Skip to main content

Peer Review reports

From: Development of an engineered peptide antagonist against periostin to overcome doxorubicin resistance in breast cancer

Original Submission
17 Jun 2020 Submitted Original manuscript
17 Jul 2020 Reviewed Reviewer Report
24 Jul 2020 Reviewed Reviewer Report
1 Sep 2020 Author responded Author comments - Khine Kyaw Oo
Resubmission - Version 2
1 Sep 2020 Submitted Manuscript version 2
3 Sep 2020 Reviewed Reviewer Report
24 Sep 2020 Reviewed Reviewer Report
25 Oct 2020 Author responded Author comments - Khine Kyaw Oo
Resubmission - Version 3
25 Oct 2020 Submitted Manuscript version 3
3 Nov 2020 Reviewed Reviewer Report
28 Nov 2020 Reviewed Reviewer Report
12 Dec 2020 Author responded Author comments - Khine Kyaw Oo
Resubmission - Version 4
12 Dec 2020 Submitted Manuscript version 4
15 Dec 2020 Author responded Author comments - Khine Kyaw Oo
Resubmission - Version 5
15 Dec 2020 Submitted Manuscript version 5
18 Dec 2020 Author responded Author comments - Khine Kyaw Oo
Resubmission - Version 6
18 Dec 2020 Submitted Manuscript version 6
Publishing
22 Dec 2020 Editorially accepted
14 Jan 2021 Article published 10.1186/s12885-020-07761-w

You can find further information about peer review here.

Back to article page